Robert W. Azelby is President, Chief Executive Officer & Director at Eliem Therapeutics, Inc. Mr. Azelby is also on the board of Clovis Oncology, Inc.

In his past career he held the position of Vice President & General Manager-Oncology at Amgen, Inc. and VP-Commercial Effectiveness Unit & General Manager at Amgen Europe BV (a subsidiary of Amgen, Inc.), President, Chief Executive Officer & Director at Alder Biopharmaceuticals, Inc. and Chief Commercial Officer & Executive VP for Juno Therapeutics, Inc.

Mr. Azelby received an undergraduate degree from the University of Virginia and an MBA from Harvard Business School.